Compare MNRO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNRO | ADCT |
|---|---|---|
| Founded | 1957 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.5M | 431.2M |
| IPO Year | 1994 | 2019 |
| Metric | MNRO | ADCT |
|---|---|---|
| Price | $15.82 | $3.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $16.00 | $7.75 |
| AVG Volume (30 Days) | ★ 1.1M | 968.6K |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.69% | N/A |
| EPS Growth | ★ 113.64 | 30.86 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $1,157,176,000.00 | $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | $66.49 |
| P/E Ratio | $525.67 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $13.51 | $2.55 |
| 52 Week High | $23.91 | $4.98 |
| Indicator | MNRO | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 36.52 |
| Support Level | $14.90 | $3.06 |
| Resistance Level | $18.24 | $4.73 |
| Average True Range (ATR) | 0.99 | 0.16 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 20.60 | 17.36 |
Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).